A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.
Giraudet, Anne-Laure; Cassier, Philippe Alexandre; Iwao-Fukukawa, Chicaco; Garin, Gwenaelle; Badel, Jean-Noël; Kryza, David; Chabaud, Sylvie; Gilles-Afchain, Laurence; Clapisson, Gilles; Desuzinges, Claude; Sarrut, David; Halty, Adrien; Italiano, Antoine; Mori, Masaharu; Tsunoda, Takuya; Katagiri, Toyomasa; Nakamura, Yusuke; Alberti, Laurent; Cropet, Claire; Baconnier, Simon; Berge-Montamat, Sandrine; Pérol, David; Blay, Jean-Yves.
; 18(1): 646, 2018 Jun 08.
Artigo em Inglês | MEDLINE | ID: mdl-29884132
α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10.
Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
High-Resolution 4D Preclinical Single-Photon Emission Computed Tomography/X-ray Computed Tomography Imaging of Technetium Transport within a Heterogeneous Porous Media.
Evaluation of sequential SPECT and CT for targeted radionuclide therapy dosimetry.